JAK inhibitor combo therapy shows promise for myelofibrosis treatment in phase 3 trial

Published Date: 21 Mar 2025

Researchers at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have demonstrated the potential for a new combination therapy to improve outcomes for patients with myelofibrosis, a rare and aggressive ...

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Aspirin Fails to Boost Survival in Colorectal Cancer Trial

2.

Do Anatomy Atlases Reflect Social Inequalities?

3.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.

4.

Some triple negative breast cancers might be avoided by longer breastfeeding

5.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot